In vitro-chemosensitivity test using the collagen gel droplet embedded culture drug test (cd-dst) for malignant pleural mesothelioma: Possibility of clinical application

Annals of Thoracic and Cardiovascular Surgery

Volumn 14, Issue 6, 2008, Pages 355-362

  Higashiyama, Masahiko ^a   Oda, Kazuyuki ^a   Okami, Jiro ^a   Maeda, Jun ^a   Kodama, Ken ^a   Takami, Koji ^b   Morinaga, Kenji ^c   Takano, Toshikazu ^d   Kobayashi, Hisayuki ^d  

^a OSAKA MEDICAL CENTER FOR CANCER AND CARDIOVASCULAR DISEASES   (Japan)

^b OSAKA NATIONAL HOSPITAL   (Japan)

^c NATIONAL INSTITUTE OF OCCUPATIONAL SAFETY AND HEALTH   (Japan)

^d Nitta Gelatin Inc   (Japan)

Author keywords

Collagen gel droplet embedded culture drug test; In vitro chemosensitivity test; Malignant pleural mesothelioma; Surgical specimen

Indexed keywords

ANTINEOPLASTIC AGENT; COLLAGEN;

ADULT; AGED; ARTICLE; BIOPSY; CELL PROLIFERATION; DRUG EFFECT; DRUG RESISTANCE; DRUG SCREENING; EVALUATION; FEMALE; GEL; HUMAN; MALE; MESOTHELIOMA; MIDDLE AGED; PATHOLOGY; PATIENT SELECTION; PLEURA TUMOR; PREDICTION AND FORECASTING; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; TISSUE CULTURE TECHNIQUE; TREATMENT OUTCOME; TUMOR CELL CULTURE;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BIOPSY; CELL PROLIFERATION; COLLAGEN; DRUG RESISTANCE, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; GELS; HUMANS; MALE; MESOTHELIOMA; MIDDLE AGED; PATIENT SELECTION; PLEURAL NEOPLASMS; PREDICTIVE VALUE OF TESTS; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; TISSUE CULTURE TECHNIQUES; TREATMENT OUTCOME; TUMOR CELLS, CULTURED;

EID: 62449325198     PISSN: 13411098     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Berghmans T, Paesmans M, Lalami Y, Louviaux I, Luce S, et al. Activity of chemotherapy and immunotherapy on malignant mesothelioma: a systematic review of the literature with meta-analysis. Lung Cancer 2002; 38: 111-21.
2. Tomek S, Manegold C. Chemotherapy for malignant pleural mesothelioma: past results and recent developments. Lung Cancer 2004; 45 (Suppl 1): S103-19.
3. Baas P. Chemotherapy for malignant mesothelioma. Lung Cancer 2005; 49 (Suppl 1): S61-4.
4. Vogelzang NJ. Standard therapy for the treatment of malignant pleural mesothelioma. Lung Cancer 2005; 50 (Suppl 1): S23-4.
5. Kobayashi H, Higashiyama M, Minamigawa K, Tanisaka K, Takano T, et al. Examination of in vitro chemosensitivity test using collagen gel droplet culture method with colorimetric endpoint quantification. Jpn J Cancer Res 2001; 92: 203-10.
6. Kobayashi H. Development of a new in vitro chemosensitivity test using collagen gel droplet embedded and image analysis for clinical usefulness. Recent Results Cancer Res 2003; 161: 48-61.
7. Kobayashi H. Collagen gel droplet culture method to examine in vitro chemosensitivity. Methods Mol Med 2005; 110: 59-67.
8. . Yasuda H, Takada T, Wada K, Amano H, Isaka T, et al. A new in-vitro drug sensitivity test (collagen-gel droplet embedded-culture drug sensitivity test) in carcinomas of pancreas and biliary tract: possible clinical utility. J Hepatobiliary Pancreat Surg 1998; 5: 261-8.
9. . Higashiyama M, Kodama K, Yokouchi H, Yokouchi H, Takami K, et al. Cisplatin-based chemotherapy for postoperative recurrence in non-small cell lung cancer patients: relation of the in vitro chemosensitive test to clinical response. Oncol Rep 2001; 8: 279-83.
10. Takamura Y, Kobayashi H, Taguchi T, Motomura K, Inaji H, et al. Prediction of chemotherapeutic response by collagen gel droplet embedded culturedrug sensitivity test in human breast cancers. Int J Cancer 2002; 98: 450-5.
11. Mori S, Kunieda K, Sugiyama Y, Saji S. Prediction of 5-f luorouracil and cisplatin synergism for advanced gastrointestinal cancers using a collagen gel droplet embedded culture. Surg Today 2003; 33: 577-83.
12. Nagai N, Minamikawa K, Mukai K, Hirata E, Komatsu M, et al. Predicting the chemosensitivity of ovarian and uterine cancers with the collagen gel droplet culture drug-sensitivity test. Anticancer Drugs 2005; 16: 525-31.
13. Kawamura M, Gika M, Abiko T, Inoue Y, Oyama T, et al. Clinical evaluation of chemosensitivity testing for patients with unresectable non-small cell lung cancer (NSCLC) using collagen gel droplet embedded culture drug sensitivity test (CD-DST). Cancer Chemother Pharmacol 2007; 59: 507-13.
14. Rusch VW. A proposed new international TNM staging system for malignant pleural mesothelioma. From the International Mesothelioma Interest Group. Chest 1995; 108: 1122-8.
15. Byrne MJ, Davidson JA, Musk AW, Dewar J, van Hazel G, et al. Cisplatin and gemcitabine treatment for malignant mesothelioma: a phase II study. J Clin Oncol 1999; 17: 25-30.
16. Kindler HL, Millard F, Herndon JE 2nd, Vogelzang NJ, Suzuki Y, et al. Gemcitabine for malignant mesothelioma: A phase II trial by the Cancer and Leukemia Group B. Lung Cancer 2001; 31: 311-7.
17. Steele JP, Shamash J, Evans MT, Gower NH, Tischkowitz MD, et al. Phase II study of vinorelbine in patients with malignant pleural mesothelioma. J Clin Oncol 2000; 18: 3912-7.
18. SØrensen PG, Bach F, Bork E, Hansen HH. Randomized trial of doxorubicin versus cyclophosphamide in diffuse malignant pleural mesothelioma. Cancer Treat Rep 1985; 69: 1431-2.
19. Sahmoud T, Postmus PE, van Pottelsberghe C, Mattson K, Tammilehto L, et al. Etoposide in malignant pleural mesothelioma: two phase II trials of the EORTC Lung Cancer Cooperative Group. Eur J Cancer 1997; 33: 2211-5.
20. Raghavan D, Gianoutsos P, Bishop J, Lee J, Young I, et al. Phase II trial of carboplatin in the management of malignant mesothelioma. J Clin Oncol 1990; 8: 151-4.
21. Tueni E, Sculier JP, Klastersky J. Phase I study of a carboplatin-etoposide combination in advanced thoracic cancer. Eur J Cancer Clin Oncol 1988; 24: 963-7.
22. Byrne MJ, Nowak AK. Modified RECIST criteria for assessment of response in malignant pleural mesothelioma. Ann Oncol 2004; 15: 257-60.
23. Morinaga K, Kishimoto T, Sakatani M, Akira M, Yokoyama K, et al. Asbestos-related lung cancer and mesothelioma in Japan. Ind Health 2001; 39: 65-74.
24. Murayama T, Takahashi K, Natori Y, Kurumatani N. Estimation of future mortality from pleural malignant mesothelioma in Japan based on an age-cohort model. Am J Ind Med 2006; 49: 1-7.
25. Higashiyama M, Kodama K, Yokouchi H, Takami K, Doi O, et al. Immunohistochemical p53 protein status in nonsmall cell lung cancer is a promising indicator in determining in vitro chemosensitivity to some anticancer drugs. J Surg Oncol 1998; 68: 19-24.
26. Ceresoli GL, Locati LD, Ferreri AJ, Cozzarini C, Passoni P, et al. Therapeutic outcome according to histologic subtype in 121 patients with malignant pleural mesothelioma. Lung Cancer 2001; 34: 279-87.
27. 12 as frontline therapy in malignant pleural mesothelioma. J Clin Oncol 2003; 21: 1556-61.
28. Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 2003; 21: 2636-44.
29. Gika M, Takeuchi K, Takanami I. Successful management of a patient with stage IIIA non-small cell lung cancer using sensitivity-based induction chemotherapy-report of a case. Gan To Kagaku Ryoho 2004; 31: 2055-8.
30. Noda T, Higashiyama M, Oda K, Higaki N, Takami K, et al. Mucoepidermoid carcinoma of the thymus treated by multimodality therapy: a case report. Ann Thorac Cardiovasc Surg 2006; 12: 273-8.